These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Pay attention to glucocorticoid-induced osteoporosis in treatment of rheumatic diseases]. Zhang X Zhonghua Nei Ke Za Zhi; 2008 May; 47(5):357-8. PubMed ID: 18953939 [No Abstract] [Full Text] [Related]
4. Bisphosphonates in patients with glucocorticoids: time for implementation. Lems WF J Rheumatol; 2009 Aug; 36(8):1570-2. PubMed ID: 19671808 [No Abstract] [Full Text] [Related]
5. [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases]. Wang QH; Wu HX; Huang YL; Xue J; Yang XY; Zhu L; Wen LH Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1888-91. PubMed ID: 19040000 [TBL] [Abstract][Full Text] [Related]
9. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Lekamwasam S; Adachi JD; Agnusdei D; Bilezikian J; Boonen S; Borgström F; Cooper C; Perez AD; Eastell R; Hofbauer LC; Kanis JA; Langdahl BL; Lesnyak O; Lorenc R; McCloskey E; Messina OD; Napoli N; Obermayer-Pietsch B; Ralston SH; Sambrook PN; Silverman S; Sosa M; Stepan J; Suppan G; Wahl DA; Compston JE; Arch Osteoporos; 2012; 7():25-30. PubMed ID: 23225278 [TBL] [Abstract][Full Text] [Related]
10. [The risk of developing osteoporosis in rheumatic diseases]. Dequeker J; Vertraeten A; Gevers D; Geusens P Klin Med (Mosk); 1989 Jul; 67(7):116-9. PubMed ID: 2811200 [TBL] [Abstract][Full Text] [Related]
11. From bone biology to clinical outcome: state of the art and future perspectives. Schett G; Saag KG; Bijlsma JW Ann Rheum Dis; 2010 Aug; 69(8):1415-9. PubMed ID: 20650876 [TBL] [Abstract][Full Text] [Related]
12. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699 [TBL] [Abstract][Full Text] [Related]
13. [Glucocorticoids in rheumatic diseases - what is the optimal dose?]. Krause D Dtsch Med Wochenschr; 2012 Sep; 137(36):1751-4. PubMed ID: 22933199 [TBL] [Abstract][Full Text] [Related]
14. [Significance of cytokines for bone loss--are there possible interventions?]. Scharla SH Z Rheumatol; 2001 Apr; 60(2):104-6. PubMed ID: 11383043 [No Abstract] [Full Text] [Related]
15. An update on glucocorticoid-induced osteoporosis. Woolf AD Curr Opin Rheumatol; 2007 Jul; 19(4):370-5. PubMed ID: 17551369 [TBL] [Abstract][Full Text] [Related]
16. Sensitivity of bone to glucocorticoids. Cooper MS Clin Sci (Lond); 2004 Aug; 107(2):111-23. PubMed ID: 15113280 [TBL] [Abstract][Full Text] [Related]
17. Corticosteroids in the treatment of rheumatologic diseases. Morand EF Curr Opin Rheumatol; 2000 May; 12(3):171-7. PubMed ID: 10803744 [TBL] [Abstract][Full Text] [Related]
18. Series on pharmacology in practice. 9. Glucocorticoids in rheumatic disease. Nelson AM; Conn DL Mayo Clin Proc; 1980 Dec; 55(12):758-69. PubMed ID: 7012460 [TBL] [Abstract][Full Text] [Related]
19. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264 [TBL] [Abstract][Full Text] [Related]
20. [Specialties in therapy of osteoporosis in inflammatory joint disease]. Franck H; Braun J; Buttgereit F; Dreher R; Hein G; Kekow J Z Rheumatol; 2004 Jun; 63(3):223-9. PubMed ID: 15224226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]